{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:41Z","timestamp":1790369981891,"version":"4.1.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijrobp.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:12:39Z","timestamp":1779376359000},"page":"715-726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["External Beam Radiation Therapy and Immunotherapy in the Management of Hepatobiliary Malignancies: A Meta-analysis of Treatment Response Rates"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-2147","authenticated-orcid":false,"given":"Juan Jose Juarez Vignon","family":"Whaley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Linton","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-965X","authenticated-orcid":false,"given":"Matthew J.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.05.002_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.17998\/jlc.2024.03.13","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J Liver Cancer"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0002","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0003","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0004","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17474124.2021.1890031","article-title":"Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.21037\/jgo-20-203","article-title":"A review of systemic therapy in biliary tract carcinoma","volume":"11","author":"Jansen","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0006","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0011","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0012","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"Reig","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1748-717X-8-61","article-title":"Determination of the \u03b1\/\u03b2 ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma","volume":"8","author":"Son","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0014","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"van Leeuwen","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0015","article-title":"Analysis of hepatocellular carcinoma stereotactic body radiation therapy dose prescription method using uncomplicated tumor control probability model","volume":"6","author":"Cheung","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.1130","article-title":"Efficacy and safety of PD-1 inhibitors and targeted drugs combined with radiotherapy in first-line treatment of oligometastatic hepatocellular carcinoma","volume":"120","author":"Zhu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12916-024-03381-4","article-title":"Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"Zhu","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JHC.S480691","article-title":"Impact of timing the combination of radiotherapy and PD-1 inhibitors on outcomes in patients with hepatocellular carcinoma","volume":"12","author":"Zhong","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0019","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ijrobp.2022.03.019","article-title":"The combination of radiation therapy and immunotherapy is effective and well-tolerated for unresectable biliary tract cancer","volume":"113","author":"Chen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000514400","article-title":"Real-world data on clinical outcomes of patients with liver cancer: A prospective validation of the National Cancer Centre Singapore Consensus Guidelines for the management of hepatocellular carcinoma","volume":"10","author":"Chew","year":"2021","journal-title":"Liver Cancer."},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12254-018-0431-z","article-title":"Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?","volume":"11","author":"Pinter","year":"2018","journal-title":"Memo"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0022","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0023","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/JHC.S342266","article-title":"Recurrent hepatocellular carcinoma: Patterns, detection, staging and treatment","volume":"9","author":"Papaconstantinou","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0024","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41379-020-00671-z","article-title":"Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning","volume":"34","author":"Saito","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.21037\/jgo-21-868","article-title":"Anatomic patterns of recurrence in biliary tract cancers: Does primary tumor site matter?","volume":"13","author":"Sinnamon","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.776863","article-title":"Recurrent intrahepatic cholangiocarcinoma - review","volume":"11","author":"Bekki","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0027","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000533425","article-title":"Survival outcome analysis of stereotactic body radiotherapy and immunotherapy (SBRT-IO) versus SBRT-alone in unresectable hepatocellular carcinoma","volume":"13","author":"Chiang","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0028","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.3748\/wjg.v29.i24.3871","article-title":"Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: A phase II clinical trial","volume":"29","author":"Chen","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0029","article-title":"Toripalimab in combination with anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.798832","article-title":"Combined stereotactic body radiotherapy and immunotherapy versus transarterial chemoembolization in locally advanced hepatocellular carcinoma: A propensity score matching analysis","volume":"11","author":"Chiang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0031","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12072-022-10396-7","article-title":"Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: A single-arm trial","volume":"16","author":"Li","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0032","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/CM9.0000000000003124","article-title":"Radiotherapy enhances efficacy of PD-1 inhibitors in advanced hepatocellular carcinoma: A propensity-matched real-world study","volume":"137","author":"Hsu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0033","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/cancers16040838","article-title":"Outcome of atezolizumab plus bevacizumab combination therapy in high-risk patients with advanced hepatocellular carcinoma","volume":"16","author":"Hwang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0034","article-title":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study","volume":"6","author":"Kim","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0035","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.2147\/JHC.S432542","article-title":"Effectiveness and safety of the PD-1 inhibitor lenvatinib plus radiotherapy in patients with HCC with main PVTT: Real-world data from a tertiary centre","volume":"10","author":"Li","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0036","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0037","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.ijrobp.2019.06.279","article-title":"The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma","volume":"105","author":"Smith","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0038","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1093\/oncolo\/oyae048","article-title":"Concurrent atezolizumab plus bevacizumab and high-dose external beam radiotherapy for highly advanced hepatocellular carcinoma","volume":"29","author":"Su","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0039","first-page":"1606","article-title":"Proton beam radiotherapy combined with anti-PD1\/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma","volume":"12","author":"Su","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0040","article-title":"Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e16205","article-title":"Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0042","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.839605","article-title":"Effects of stereotactic body radiation therapy plus PD-1 inhibitors for patients with transarterial chemoembolization refractory","volume":"12","author":"Xiang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0043","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.ijrobp.2024.03.035","article-title":"Stereotactic body radiotherapy combined with lenvatinib with or without PD-1 inhibitors as initial treatment for unresectable hepatocellular carcinoma","volume":"120","author":"Wang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0044","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.annonc.2023.09.2104","article-title":"958P Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study","volume":"34","author":"Xue","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1508028","article-title":"Prognostic significance of early alpha fetoprotein and des-gamma carboxy prothrombin responses in unresectable hepatocellular carcinoma patients undergoing triple combination therapy","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0046","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/HEP.0000000000000776","article-title":"Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study","volume":"80","author":"Zhu","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0047","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-24-0286","article-title":"Nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in patients with metastatic biliary tract cancer: A randomized phase 2 study","volume":"30","author":"Markussen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0048","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0049","series-title":"Biliary tract cancers","year":"2025"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijrobp.2019.01.076","article-title":"Protons versus photons for unresectable hepatocellular carcinoma: Liver decompensation and overall survival","volume":"105","author":"Sanford","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0051","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/JHC.S284403","article-title":"Current understanding of ablative radiation therapy in hepatocellular carcinoma","volume":"8","author":"Mathew","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0052","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0053","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jhep.2017.02.022","article-title":"Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis","volume":"67","author":"Sapisochin","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0054","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: An ASTRO Clinical Practice Guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0057","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.3390\/cancers15205068","article-title":"The role of carbon ion therapy in the changing oncology landscape \u2013 A narrative review of the literature and the decade of carbon ion experience at the Italian National Center for Oncological Hadrontherapy","volume":"15","author":"Orlandi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.888446","article-title":"Emerging role of carbon ion radiotherapy in reirradiation of recurrent head and neck cancers: What have we achieved so far?","volume":"12","author":"Bhattacharyya","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0059","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/21645515.2020.1840254","article-title":"Effect of radiotherapy on T cell and PD-1\/PD-L1 blocking therapy in tumor microenvironment","volume":"17","author":"Chen","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100669","article-title":"Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials","volume":"6","author":"Zhang","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0061","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: The dawn of cancer treatment","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0062","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47910-1","article-title":"Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling","volume":"9","author":"De Sousa Linhares","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0063","doi-asserted-by":"crossref","first-page":"S1575","DOI":"10.1016\/j.annonc.2022.10.376","article-title":"338P Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis","volume":"33","author":"Wei","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ijrobp.2026.05.002_bib0064","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3389\/fimmu.2018.03107","article-title":"Combining radiotherapy with anti-angiogenic therapy and immunotherapy: A therapeutic triad for cancer?","volume":"9","author":"Goedegebuure","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0065","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2010.06.018","article-title":"Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma","volume":"81","author":"Ghafoori","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0066","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: A systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.05.002_bib0067","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626007170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626007170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:07:14Z","timestamp":1790366834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626007170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0360301626007170"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.05.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External Beam Radiation Therapy and Immunotherapy in the Management of Hepatobiliary Malignancies: A Meta-analysis of Treatment Response Rates","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}